INTRODUCTION
Adverse drug reactions (ADRs) are a leading cause of morbidity and mortality. 1,2 ADRs have been estimated to account for up to 106,000 deaths annually in the United States. 1,2 Additionally, ADRs are the cause of hospital admission in 3% to 6% of patients of all ages 3,4 and 3% to 24% of elderly patients. 5 The incidence of fatal ADRs has been found to be 0.15% to 0.41% in Western countries. 1,4 In the United States, ADR-related morbidity and mortality costs have been estimated at US $30 billion to US $130 billion annually. 6, 7 ADRs are generally defined as any undesirable effbct of a drug beyond its anticipated therapeutic effect that occurs during clinical use. s Although many ADRs are mild and disappear when the causative drug is discontinued or the dose is reduced, some are serious and permanent. Therefore, ADRs might increase not only morbidity and mortality but also health care costs.
A nationwide ADR reporting system was established in Taiwan in 1986, but no statistical analysis data have been previously reported. Although the clinical pharmacy departments in all hospitals in Taiwan contribute to the ADR reporting and monitoring programs, the reporting rate of physicians remains low (0.003%), 9 compared with rates reported in the United States (0.19%) 9 and Australia (1.09%). 1° The aim of this study was to analyze the characteristics of all ADRs reported in our hospital, including the incidence of ADRs, the classes of drugs that were most commonly associated with ADRs, the relation of the drugs with the ADRs, the type and severity of each ADR, and the direct medical costs to the hospital.
PATIENTS AND METHODS
This prospective, descriptive, observational study was conducted from January 1, 2002, to December 31, 2004, at the 1083-bed Chi Mei Medical Center, a tertiary teaching hospital in ~lhinan, Taiwan. Institutional review-board approval was not required for this study. Patient confidentiality was maintained throughout the course of the study. The medications associated with the ADRs were classified in accordance with the hospital formulary. ADRs were defined according to the World Health Organization as "any response to a drug which is noxious and unintended, and which occurs at doses normally used in humans for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function. ' '8 Patients who experienced ADRs during their hospital stay or were admitted due to ADRs were identified and included in the study. The ADR reporting system involves both active and passive methods routinely conducted in Taiwanese hospitals. Active methods included the identification, by clinical pharmacists, of any suspected ADRs through ward rounds and prescribed drugs (eg, naloxone for the reversal of narcotic depression). The passive method was spontaneous reports from pharmacists, physicians, and nurses (hereafter called reporters) of suspected ADRs using a computerized automatic reporting system or paper ADR reporting forms. All cases were reviewed by clinical pharmacists to exclude ADRs reported in duplicate through the 2 reporting methods. Any suspected ADRs were reported by entering the name of reporter and units, patients' brief data, the name of suspected drugs, and suspected ADR. Patients who developed an ADR during hospitalization and patients whose admission resulted from an ADR were assessed by a clinical pharmacist and their responsible physicians on receipt of the ADR reporting fbrrn using the Naranjo algorithm. 11 ADRs were classified as def~elite (score 9 or 10), probable (5 8) , possible (1~1), or doubtful (0) in regard to their relation with a particular drug. ADR severity was assessed according to the criteria developed by ttartwig et al. 12 This scale categorized each ADR as mild, moderate, or severe.
A probability category for each ADR was assigned according to the Naranjo scale. M The cause of an ADR was considered type A (augmented pharmacologic ef}bcts) or B (idiosyncratic). 13 ADRs were defined as miM if they were self21imiting, resolved over time without treatment, and did not affect the length of hospitalization.
Moderate ADRs were those that required therapeutic intervention, prolonged hospitalization by 1 day, or caused the patient to be admitted to the hospital. Severe ADRs were those that were life threatening, carcinogenic, or permanently disabling, prolonged hospitalization by >1 day, or caused death, s Patient ADR outcomes were reported as follows: fully recovered; not fully recovered; death; or unknown.
To measure the impact of ADRs on direct medical costs and length of stay, data were collected from the hospital's claims database. The extra days of stay associated with ADRs were marked as the difference between the beginning and end of the ADR. The beginning of the ADR was the date of hospital admission due to the ADR or, if the event occurred during hospitalization, the date of the clinical or biological diagnosis of the ADR. The end of the ADR was the date of hospital discharge or the date of normalization of the effect, including the date of laboratory examination with normal results or the disappearance of clinical symptoms reported by physicians during hospitalization. The direct medical cost incurred in treating the ADRs was calculated for each medical service, physician fee, and laboratory test (by day rate) based on the hospital's claims data system. For ADRs requiring discontinuation of the suspected drugs, the cost for treatment was considered as zero. When ADRs required extra medications, treatments, or laboratory tests, the costs of these (eg, all drug costs, physician fees, pharmacist dispensing fees, laboratory test fees, room charges) were included in calculating the cost incurred by the patient.
STATISTICAL ANALYSIS
Descriptive analysis was conducted for quantitative variables. Mean values and the X 2 test were used to compare the distributions of categorical variables. Data are presented as mean (SD). Categorical variables are expressed as a percentage of the total number of ADRs. P < 0.05 was considered statistically significant.
RESULTS
During the study period, 43 of the 142,295 hospitalized patients (0.03%) were admitted because of an ADR. A total of 564 (0.40%) of the hospitalized patients were verified to have ADRs (318 males [56.4%]; mean [SD] age, 66 [2] years). The age distribution of patients with ADRs and of the general popuhtion of hospitalized patients is shown in Table I .
The correlation of ADR rate with gender was not statistically significant (Table II) . ADR rates increased with age from 1.34/1000 patients for the age range of 0 to 10 years to 6.95/1000 patients for the age range of 71 to 100 years (P < 0.001) ( Table III) .
All 564 ADRs were detected by either the active or the passive ADR reporting system. Clinical pharmacists reported 257 of the ADRs (45.6%), nurses reported 204 (36.2%), and physicians reported 85 (15.1%). The remaining 18 (3.2%) were reported by the patient or a family member.
The therapeutic classes of the drugs associated with the ADRs are shown in Table IV . Antibiotics were the most frequent cause of ADRs, with 219 patients (38.8%) experiencing an ADR associated with this drug class.
The most common clinical manifestations of the ADRs are listed in (Table V) , with most cases being classified as mild, resolved with the highest recovery rates (75%), and caused by the first-generation cephalosporin cephazolin. The most severe dermatologic ADR was Stevens Johnson syndrome; 2 patients experiencing this reaction died. Hematologic ADRs were the second most frequently rated as severe in intensity (11/61 [18%]); thrombocytopenia was the most frequently occurring (6.9%). Regarding the probability of ADRs, 413 of ADRs (73.2%) reported were identified as probable, indicating that they were more likely to be associated with the suspected drug, according to the Naranjo probability scale. 11 Two reported ADRs (0.4%) were considered doubtful. The majority of ADRs (474 [84.0%]) reported were considered predictable, type B reactions (Table VII) .
Gastrointestinal ADRs had the lowest recovery rates (1/28 [3.6%]), because most of the patients experienced vomiting and diarrhea and were not fully recovered before discharge; however, none of these reactions resulted in death (Table VIII) .
Hospitalizations or extensions of hospitalization due to ADRs accounted for a total of 530 additional days of hospitalization (Table IX) . The total cost of treating ADRrelated illness collected from the hospital claims data was estimated to be US $150,027.14 ( Table X) . The cost of treating each ADR that was associated with extended hospitalization (n 42) was estimated to be US $3489.00. 
DISCUSSION
In this study, we found that 0.03% (43/142295) of hospitalized patients were admitted because of an ADR. A total of 564 (0.40%) hospitalized patients experienced an ADR during their hospital stay. These figures appear much lower than data from published studies f~om other countries (2.9% 35.0%). 3'4'14 Physicians in Taiwan may underreport ADRs, even though most medical centers have a well-established ADR reporting system connected to the central reporting center. Clinical pharmacists also promote ADR reporting through presentations about ADRs at physicians' morning meetings and through promotional materials and a newsletter. Additionally, ADR reporting is a basic requirement of hospital accreditation in Taiwan. However, the ADR reporting rate remains low (0.003%), possibly due to physicians' concerns about liability. This phenomenon may also occur in Western countries. 15 One study reported that their ADR-reporting method supported the observation of traditional ADRs reporting are markedly underreported in hospitalized patients because the reporting system is physician dependent.l~ We found that the proportion of ADR-related hospitalizations increased with age from 0.22% in patients aged <21 years to 0.69% in patients aged >71 years, which confirms a previous study that found that older patients have significantly more ADR-related problems. 17 This observation suggests that increasing age is a risk factor for the occurrence of ADRs, which might be related to the increased number of drugs elderly patients receive, the use of drugs that are inappropriate for elderly patients, and the number of previous illnesses. 17,18
ADR rates did not vary significantly by gender in our study, which differed from the findings of previous studies. 19,20 They found that female sex was associated with a greater number of ADR-related problems. As reported in previous studies, 21 the most connnonly affected organ system associated with ADRs in our study was the skin (52.5 %). Two patients died of allopurinolrelated Stevens-Johnson syndrome, which is the second most connnon drug associated with fatal ADRs. 22 Consistent with published studies, 2°,21 the ADRs in our study were most frequently associated with antibiotics (38.8%), analgesics (11.0%), and cardiovascular drugs (9.9%). The most common ADR was rash related to treatment with cephazolin.
A probability category for each ADR was assigned based on the Naranjo scale. 11 The results of the assessment were submitted to the Pharmaceutical and Therapeutic (P&T) Committee of our hospital for further evaluation. The results of the P&T evaluation were then reported to the National Adverse Drug Reporting Center of Taiwan.
12"7
Our hospital incurred a mean of US $283 for 1 additional length of stay associated with an ADR. One study 23 identified longer hospital stays as directly contributing to increased ADR costs. Two studies 2,23 concluded that the increase in the cost of hospitalization for an ADR was US $3800 and US $3200, respectively. Another study 24 found that the mean additional cost of hospitalization for an ADR was US $1400. In our study, the mean cost of an ADR associated with extended hospitalization was US $3489. The higher costs determined by some previous studies might be due to the severity of the ADRs, as patients with cardiovascular and hemorrhagic ADRs related to cardiovascular or anticoagulant drugs may be transferred to the intensive care unit. 25 However, the severe ADRs in our study were hematologic and cutaneous (ie, StevensJohnson syndrome, neutropenia, thrombocytopenia).
A limitation of this study was that the rate of ADR-related hospitalization was probably an underestimate because of underreporting or misclassification, because all ADRs possibly were not identified. 2(5 The actual number of ADRs in our patients might also have been higher than the number of ADRs detected during hospitalization because of the relatively short length of stay in our hospital (mean, 7 days). Therefore, some ADRs triggered by the drugs used during hospitalization may have occurred in the outpatient department.
CONCLUSION
In this hospital, 0.40% of patients were identified as having ADRs that were associated with high direct costs, mostly due to extended hospitalizations.
